Midomafetamine is another name for methylenedioxymethamphetamine (MDMA), a synthetic psychoactive stimulant/hallucinogen. In illicit contexts it is commonly called ecstasy or molly. U.S. DEA materials classify MDMA as Schedule I with no approved medical use.
Compass Pathways announced positive Phase 3 data for COMP360 psilocybin therapy in treatment-resistant depression, showing statistically significant improvements in depression scores and durability through 26 weeks, with plans to file for FDA approval in Q4 2026.
Compass Pathways' COMP360 synthetic psilocybin met primary endpoints in Phase 3 trials for treatment-resistant depression, with the company planning to submit a new drug application in Q4 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06418178 |
Dose Optimization of MDMA-Assisted Therapy for PTSD |
RECRUITING | PHASE2 |
| NCT05173831 |
Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans |
WITHDRAWN | PHASE2 |
| NCT05147402 |
Food Effects on Bioavailability of MDMA in Healthy Volunteers |
COMPLETED | PHASE1 |
| NCT04968938 |
Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD |
WITHDRAWN | PHASE2 |
| NCT04784143 |
Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD |
TERMINATED | PHASE2 |
| NCT04454684 |
A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders |
WITHDRAWN | PHASE2 |
| NCT04438512 |
A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD |
NO_LONGER_AVAILABLE | |
| NCT04077437 |
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2) |
COMPLETED | PHASE3 |
| NCT03282123 |
Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD |
COMPLETED | PHASE2 |
| NCT03181763 |
Evaluation of MDMA on Startle Response |
COMPLETED | PHASE1 |
